focus -WSS

focus

author：focus 2025-08-19 15:02:22 - browse：5

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Illumina to lay off 10% of research and development team

Wikipedia

WSS

Newly formed Hurricane Beatriz sweeps close to Mexico's southwest Pacific coast

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

The Sacklers, horror, and ‘The Fall of the House of Usher’

Biden slams SCOTUS affirmative action decision: 'Discrimination still exists in America'

Biotech incubator Curie.Bio graduates its first startup

The simple reason for the increase in autism diagnosis

focus

focus

leisure time

Apple is now the first public company to be valued at $3 trillion

More doctors should go into startup world

DIEP, the 'gold standard' of breast reconstruction, is under threat

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

After affirmative action ruling, medical educators look to 'holistic review'

10 million people disenrolled from Medicaid over past six months

How one medical school became remarkably diverse

Here's how to stay safe from wildfire smoke amid reduced air quality

Novavax promises a turnaround & Lilly roils the obesity market

FDA approves potent Eli Lilly obesity drug, Zepbound

hotspot

Medical experts exlpore how to eliminate bias in clinical algorithms

Excited delirium, Elijah McClain, and emergency physicians

HPV cancer vaccine study demonstrates efficacy

A clever new way to fix Medicaid and graduate medical education

Sanofi CEO defends move to abandon profit guidance, boost research

Thousands protest in Iraq for a second day over burning of Quran in Sweden

Wikipedia

explore

Wikipedia

explore